Skip to main content

Table 2 Univariate relationships between the demographic and clinical characteristics and the outcome

From: Predicting the outcome in confirmed COVID-19 patients with coronary artery disease: a key role for the first chest computed tomography

  Outcome +
n=17
Outcome −
n=31
OR (95% CI) Effect size**
Sex    1.13 (0.29–4.49) 0.059
 Male 13 (36.1) 23 (63.9)   
 Female 4 (33.3) 8 (66.7)   
Diabetes mellitus    0.51 (0.15–1.730) 0.317
 Yes 6 (27.3) 16 (72.7)   
 No 11 (42.3) 15 (57.7)   
Hypertension    3.37 (0.80–4.18) 0.345
 Yes 14 (43.6) 13 (56.4)   
 No 3 (18.8) 13 (81.2)   
ACEI/ARB    0.93 (0.28–3.03) 0.073
 Yes 9 (34.6) 17 (65.4)   
 No 8 (38.1) 13 (61.9)   
History of renal failure    1.24 (0.19–8.29) 0.105
 Yes 2 (40) 3 (60)   
 No 15 34.9) 28 (65.1)   
LVEF, number of patients/total patients    0.71 (0.15–3.50) 0.158
 > 35% 9/26 (34.6) 17/26 (65.4)   
 ≤ 35% 3/11 (27.3) 8/11 (72.7)   
 LVEF*, n=37 52 (29, 55) 43 (32, 55) 1.01 (90.96–1.07) 0.110
BUN/Cr > 20    1.87 (90.51–6.88) 0.305
 Yes 6 (46.2) 7 (53.8)   
 No 11 (31.4) 24 (68.6)   
Age, year 61.9 ± 16.2 60.3 ± 11.2 1.01 (0.96–1.06) 0.122
BMI, n=44 28.8 ± 5.7 27.4 ± 4.5 1.06 (0.93–1.21) 0.284
hs-CRP* 7.4 (2.8, 12.2) 3.2 (0.7, 8.7) 1.07 (0.97–1.02) 0.327
CT score* 6 (2.5, 11) 1 (0, 2) 1.38 (1.12–1.70) 0.634
LVEF*, n=37 52 (29, 55) 43 (32, 55) 1.01 (90.96–1.07) 0.110
  1. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; LVEF, left ventricular ejection fraction; BUN, blood urea nitrogen; Cr, creatinine; CT, computed tomography; BMI, body mass index; hs-CRP, highly sensitive C-reactive protein
  2. *Median (25%, 75%)
  3. **Effect size was calculated as the Cohen h for the categorical variables, the Cohen d for age and BMI, and the rank-biserial correlation for hs-CRP, the CT score, and LVEF